Early Phase Clinical Trial Units (EPCTU)
Award Notice Posted
- Solicitation number
- 75N93022D00016
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Dynport Vaccine Company LLC
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93022D00016 Federal IDV award
Notice details come from SAM.gov. Updated .
About this opportunity
This Award Notice from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a contract to DynPort Vaccine Company LLC on January 14, 2022 for $346,610,277 to implement multiple indefinite delivery/indefinite quantity contracts for Early Phase Clinical Trial Units. The contracts will support Phase 0 to Phase II clinical trials, including proof-of-concept studies in healthy and diseased human populations domestically and internationally, aided by bioanalysis when necessary, with a minimum value of $10,000 per award under the total estimated value of $346,610,277.
Notice text
See Attachment for RFP-NIAID-NIH-AI-75N93020R00023.
Awarded contract 75N93022D00016 to DynPort Vaccine Company LLC for 346610277.00 on 2022-01-14.
Files
| File | Type | Posted |
|---|---|---|
| RFP-NIAID-NIH-AI-75N93020R00023 Final.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Early Phase Clinical Trial Units (EPCTU) | Award Notice | |
| Early Phase Clinical Trial Units (EPCTU) | Award Notice | |
| Early Phase Clinical Trial Units (EPCTU) | Award Notice | |
| This notice | Award Notice | |
| Early Phase Clinical Trial Units (EPCTU) | Solicitation | |
| Early Phase Clinical Trial Units (EPCTU) | Pre-Solicitation |
6 of 7 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity